Secondary prevention of cardiovascular disease in high-risk patients diagnosed with cardiovascular disease (status post myocardial infarction or stroke, peripheral arterial disease), type 2 diabetes, or moderate to severe chronic kidney disease (CKD 4-5): in patients who cannot be diagnosed with FH according to Dutch criteria, although they have lipid disorders and do not achieve their LDL-C targets, according to the adopted guidelines (), and in whom all other standard therapies have failed (for at least 3 months) or are poorly tolerated, and/or there are contraindications to pharmacological treatment (adverse effects, complications, e.g
The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia
Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research
Mental Health Applications Show Promise in Animals But Lack Human Evidence The chasm between preclinical promise and clinical reality defines BPC-157s mental health profile
After treatment, temporary redness or swelling can occur
Biosci Biotechnol Biochem 56:689 Yan SH, Dufour JP, Meurens M (2003) Synthesis and characterization of highly pure theanine